Research programme: bispecific mRNA therapeutics - Celon Pharma
Latest Information Update: 26 Apr 2023
At a glance
- Originator Celon Pharma
- Class Antineoplastics; RNA
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 31 Mar 2023 Early research in Solid tumours in Poland (Parenteral) (Celon Pharma Pipeline, March 2023)